30 completed, 15 terminated, 8 recruiting, 5 unknown. 66 Phase 2, 14 Phase 1, 4 Phase 3.
Follow Myeloma: new trials by email Literature Review of Myeloma trials Research Report on Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma Etentamig, Isatuximab, Bortezomib + Lenalidomide + Dexamethasone - Myeloma Multiple, Myeloma | Phase 1 / Phase 2 | Not yet recruiting | Universitätsklinikum Hamburg-Eppendorf | 220 | 2026-12-01 | 2026-05-20 |
| A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma Siltuximab - CRS - Cytokine Release Syndrome, Myeloma | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2025-08-10 | 2025-08-06 |
| Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma Elranatamab - Myeloma | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 39 | 2025-05-27 | 2025-12-03 |
| Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig) Trimethoprim / Sulfamethoxazole, Immune Globulin Intravenous - Myeloma, Non Hodgkin's Lymphoma | Phase 2 / Phase 3 | Recruiting | Monash University | 900 | 2025-05-07 | 2025-10-07 |
| Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT) Intravenous immunoglobulin, Trimethoprim / Sulfamethoxazole, Amoxicillin clavulanic acid - Myeloma, Non-Hodgkin's Lymphoma | Phase 2 / Phase 3 | Recruiting | Monash University | 900 | 2025-05-06 | 2025-10-07 |
| Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig) Trimethoprim Sulfamethoxazole, Amoxycillin/clavulanic acid, Immune Globulin Intravenous - Myeloma, Leukemia | Phase 2 / Phase 3 | Recruiting | Monash University | 900 | 2025-05-06 | 2025-10-07 |
| Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig) Immune Globulin Intravenous - Myeloma, Non Hodgkin's Lymphoma | Phase 2 / Phase 3 | Recruiting | Monash University | 900 | 2025-04-28 | 2025-10-07 |
| PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab) Tocilizumab before CAR-T cell infusion, Tocilizumab at emerging CRS - Myeloma, Lymphoma | Phase 2 | Recruiting | Insel Gruppe AG, University Hospital Bern | 100 | 2024-07-01 | 2024-07-08 |
| Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation Fecal Microbiota Transplantation - Acute Leukemia in Remission, Myelodysplastic Syndromes | Phase 2 | Recruiting | University Hospital, Clermont-Ferrand | 150 | 2022-12-20 | 2026-09-21 |
| Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients Selinexor, Clarithromycin, Pomalidomide - Myeloma Multiple, Myeloma | Phase 2 | Terminated | Weill Medical College of Cornell University | 4 | 2021-12-29 | 2023-10-25 |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. Elranatamab - Elranatamab, Myeloma | Phase 2 | Completed | Pfizer | 39 | 2021-12-21 | 2026-09-29 |
| SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations BMS-986414, BMS-986413 - SARS-CoV2 Infection, SARS-CoV-2 Acute Respiratory Disease | Phase 2 | Withdrawn | Imperial College Healthcare NHS Trust | 2021-11-29 | 2023-04-24 | |
| Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma Belantamab mafodotin - Myeloma | Phase 2 | Active not recruiting | University of Pennsylvania | 41 | 2021-06-02 | 2026-10-14 |
| VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma bortezomib, Lenalidomide, Dexamethasone - Myeloma, Newly Diagnosed | Phase 2 | Unknown | Sun Yat-sen University | 50 | 2020-09-25 | 2023-06-18 |
| A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment Bortezomib Injection - Myeloma, Myeloma Multiple | Phase 2 | Terminated | AHS Cancer Control Alberta | 39 | 2020-05-29 | 2026-10-28 |
| Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma Daratumumab, Bortezomib, Dexamethasone - Multiple Myeloma, Myeloma | Phase 2 | Unknown | Singapore General Hospital | 27 | 2019-10-02 | 2023-07-10 |
| PROactive Evaluation of Function to Avoid CardioToxicity MyoStrain® - Cardiotoxicity, Breast Cancer | Phase 2 | Terminated | Washington University School of Medicine | 49 | 2019-03-13 | 2025-07-29 |
| Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma Daratumumab, Carfilzomib, Lenalidomide - Myeloma, Multiple Myeloma | Phase 2 | Active not recruiting | University of Chicago | 75 | 2019-02-13 | 2026-04-13 |
| Effects of Hyperbaric Oxygen (HBO) on Blood Count Recovery After Autologous Hematopoietic Stem Cell (HSPC) Transplant for Multiple Myeloma Hyperbaric Oxygen Therapy, No Hyperbaric Oxygen Therapy - Myeloma | Phase 2 | Completed | Omar Aljitawi | 99 | 2018-05-10 | 2025-02-07 |
| Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment. Carfilzomib, Lenalidomide, PET-CT - Myeloma | Phase 2 | Active not recruiting | Oslo University Hospital | 53 | 2018-03-16 | 2025-08-08 |
Showing 20 of 66. Sign in to see all of them.
Neoplasms, Plasma Cell (66) · Multiple Myeloma (24) · Lymphoma (23) · Leukemia (18) · Hodgkin Disease (9) · Lymphoma, Non-Hodgkin (9) · Myelodysplastic Syndromes (8) · Neoplasms (6) · Infections (5) · Leukemia, Lymphocytic, Chronic, B-Cell (5) · Graft vs Host Disease (4) · Hematologic Neoplasms (4) · Leukemia, Myeloid, Acute (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Anemia, Refractory, with Excess of Blasts (3)
Neoplasms by Histologic Type (65) · Neoplasms (60) · Hemic and Lymphatic Diseases (46) · Immune System Diseases (45) · Immunoproliferative Disorders (45) · Lymphoproliferative Disorders (45) · Hematologic Diseases (40) · Lymphatic Diseases (28) · Cardiovascular Diseases (24) · Hemorrhagic Disorders (24) · Blood Protein Disorders (23) · Hemostatic Disorders (23) · Paraproteinemias (23) · Vascular Diseases (23) · Bone Marrow Diseases (11)
Dexamethasone (14) · Bortezomib (11) · Melphalan (11) · Cyclophosphamide (7) · Lenalidomide (7) · Calcium Dobesilate (6) · Granulocyte Colony-Stimulating Factor (6) · fludarabine (5) · Busulfan (4) · Filgrastim (4) · Stem Cell Transplantation (4) · carfilzomib (4) · fludarabine phosphate (4) · Alemtuzumab (3) · Radiotherapy (3)
M.D. Anderson Cancer Center (13) · Monash University (4) · David Rizzieri, MD (3) · Insel Gruppe AG, University Hospital Bern (3) · H. Lee Moffitt Cancer Center and Research Institute (2) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (2) · Singapore General Hospital (2) · University of Chicago (2) · University of Pennsylvania (2) · AHS Cancer Control Alberta (1) · Amsterdam UMC, location VUmc (1) · Centre Leon Berard (1) · Cephalon (1) · Dartmouth-Hitchcock Medical Center (1) · Emory University (1)
United States (37) · Australia (4) · China (4) · France (4) · Switzerland (4) · United Kingdom (3) · Singapore (2) · Canada (1) · Denmark (1) · Germany (1) · Italy (1) · Mexico (1) · Netherlands (1) · Norway (1) · Sweden (1)
Zoe McQuilten, Professor (4) · David Rizzieri, MD (3) · Muzaffar H. Qazilbash, MD (3) · Dolores Grosso, DNP, CRNP (2) · Maurizio Zangari, MD (2) · Neal Flomenberg, MD (2) · Aaron Rapoport, M.D. (1) · Adam Cohen, MD (1) · Amin Alousi, MD (1) · Amir A Toor, MD (1) · Amitabha Mazumder, MD (1) · Andrew Artz, MD (1) · Andy Peniket (1) · Benjamin Derman, MD (1)
PMID 18850014, PMID 19720922, PMID 20067838, PMID 20530974, PMID 20919852, PMID 23994781, PMID 24269380, PMID 24520093, PMID 24658821, PMID 24886772, PMID 25784682, PMID 26932802, PMID 28067870, PMID 28522110, PMID 29463563, PMID 29567784, PMID 30237154, PMID 31618456, PMID 34392637, PMID 37130682, PMID 38867006, PMID 39638553, PMID 40948663, PMID 41400977
P01CA124787 (2), 2025 (1)